We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Please watch the video for more information
days to go: Expired investment: £257,501
Hybrid Air Vehicles (HAV) is a company that is aiming to make air travel sustainable and carbon-free. It's product, Airlander, is the world’s first full-scale hybrid aircraft. By 2025, the company estimates that Airlander will fly with up to 90% fewer emissions than other aircraft. The market for Airlander technology is estimated at over US$ 50 billion over the next 20 years. HAV is focusing on securing launch orders for the production of Airlander 10, it's all-electric aircraft, from commercial and defence contractors. The company has featured in publications such as The Telegraph, Financial Times, BBC, GQ and Robb Report. HAV will use the investment to underpin its operations and contract discussions during Covid-19 recovery.
days to go: Expired investment: £1,900,490
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
Pashley, the UK's most enduring bicycle manufacturer established in 1926, has been crafting hand-made bicycles for 97 years. Renowned for our classic designs, we also specialize in innovative products catering to a greener transport market. Our product offerings encompass three primary categories: Cargo Cycles which is Ideal for last-mile delivery, vending, and promotional purposes; Bike Share: Providing hire bikes and docks tailored for urban settings & Classic Cycles: Exquisite, traditionally hand-built bicycles for town and country rides.
days to go: Expired investment: £657,702
EV Hub plans to offer fast charging for fleets of electric cars, vans, and couriers at sites with 15-30 bays each. The company uses the latest stable technology that needs only c.30 minutes per charge in comparison to 1-2 hours ‘Fast’ chargers and overnight for ‘Slow’ home/work charging. EV Hub's goal is to start with London’s 3,000 electric taxis, and it will expand quickly to serve vans, hire cars, minicabs, and couriers. With the proceeds, the company will lease and run two first flagship, high-traffic sites, King’s Cross and Heathrow Airport, which will help boost the working capital to profitability.

Pitch Rated

73%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Argento Labs, a UK-based biotech company, is dedicated to converting waste into valuable resources, leading the way in sustainable innovation. They utilize patented bioprocessing technology to extract sugars, proteins, and fats from agricultural, forestry, and municipal waste. Their product range includes alternative proteins, biogenic CO2, and bio-fertilizers, contributing to environmental sustainability and decarbonization efforts. Argento Labs focuses on scalability for industrial production to support a sustainable future and envisions waste as a transformative solution for preserving the planet. Their patent currently applies in the US jurisdiction.
days to go: Expired investment: £415,233
A new form of electric transport in the bike industry with the use of an affordable and simple conversion kit. Swytch have developed a kinetically rechargeable add-on for existing bikes to convert them into eBikes for a range of up to 50 miles. Funding will result in additional units being manufactured and sold at a 70% margin. The products are available online and currently via 20 independent bike dealers, with over 100 more waiting on stock.
days to go: Expired investment: £349,356
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph